Implantable CAR T cell factories enhance solid tumor treatment

• Chimeric Antigen Receptor (CAR) T cell therapy has produced revolutionary success in hematological cancers such as leukemia and lymphoma. Nonetheless, its translation to solid tumors faces challenges due to manufacturing complexities, short-lived in vivo persistence, and transient therapeutic impact. We introduce 'Drydux' - an innovative macroporous biomaterial scaffold designed for rapid, efficient in-situ generation of tumor-specific CAR T cells. Drydux expedites CAR T cell preparation with a mere three-day turnaround from patient blood collection, presenting a cost-effective, streamlined alternative to conventional methodologies. Notably, Drydux-enabled CAR T cells provide prolonged in vivo release, functionality, and enhanced persistence exceeding 150 days, with cells transitioning to memory phenotypes. Unlike conventional CAR T cell therapy, which offered only temporary tumor control, equivalent Drydux cell doses induced lasting tumor remission in various animal tumor models, including systemic lymphoma, peritoneal ovarian cancer, metastatic lung cancer, and orthotopic pancreatic cancer. Drydux's approach holds promise in revolutionizing solid tumor CAR T cell therapy by delivering durable, rapid, and cost-effective treatments and broadening patient accessibility to this groundbreaking therapy.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Biomaterials

CAR T cell

Cell therapy

immunotherapy

implant

porous matrix

Cost effectiveness

Cytology

Diseases

Oncology

Patient treatment

Scaffolds (biology)

Tumors

alginic acid

biomaterial

chimeric antigen receptor

drydux

gamma interferon

interleukin 15

interleukin 2

macrophage inflammatory protein 1alpha

Antigen receptors

Chimeric antigen receptor T cell

In-vivo

Manufacturing complexity

Porous matrixs

Solid tumors

Tumor treatment

A-549 cell line

animal experiment

animal model

animal tissue

antineoplastic activity

Article

bioluminescence

chimeric antigen receptor T-cell immunotherapy

computer assisted tomography

controlled study

cytotoxicity

enzyme linked immunosorbent assay

female

flow cytometry

human

human cell

immunofluorescence

lung metastasis

mouse

nonhuman

nuclear reprogramming

ovary cancer

overall survival

PANC-1 cell line

pancreas cancer

peripheral blood mononuclear cell

peritoneum

phenotype

SK-OV-3 cell line

solid tumor

tumor growth

tumor microenvironment

tumor regression

tumor volume

T-cells

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)